About this Journal Submit a Manuscript Table of Contents

Age Macular Degeneration: Etiology, Prevention, Individualized Therapies, Cell Therapy, and Tissue Engineering

Call for Papers

Age macular degeneration (AMD) is one of the leading causes of vision loss and is the most common cause of legal blindness in industrialized countries. The dramatic loss of autonomy and life quality associated with AMD leads to increased costs for health care and long-term care. As AMD is caused by degeneration of the retina mainly due to processes related to ageing, its prevalence and the associated costs for health care are expected to increase as the population ages. The aetiology of AMD is unknown; however, the development of AMD is dependent on genetic as well as environmental factors as diet and smoking. Above all, age is the most prevalent factor, and rates increase significantly in individuals older than 50 years. A portion of patients with neovascular AMD can be treated with inhibitors of vascular endothelial growth factor (VEGF), but no treatments are available for the nonvascular one. So preventive strategies, improving the use of current pharmacologic treatments, and the development of new therapies are the main challenges in the future management of this disease.

The main focus of the special issue is the recent developments in preventive and therapeutic strategies in age macular treatment. Original research articles, reviews, and clinical studies’ are welcomed. Potential topics include, but are not limited to:

  • Socioeconomics burden of AMD
  • Genetic risk factors in AMD
  • Environmental risk factors in AMD
  • Dietary supplements in AMD
  • Early diagnosis in AMD
  • Individualized treatment protocols in wet AMD
  • Pharmacogenetic response in wet AMD
  • Future therapies in wet AMD
  • Future therapies in dry AMD
  • Mutations affecting the photopigment cycle: perspectives for individualized therapy
  • Slow delivery of drugs in AMD treatment
  • Perspectives for nanotechnology applications in AMD treatment: where do we stand?
  • Protecting and regenerating the retinal pigment epithelium in AMD: advances in pharmacology
  • Cell-based therapy in AMD
  • Tissue-engineered therapy in AMD
  • Vision rehabilitation strategies in AMD
  • Retinal prosthesis and implants: the newest developments

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/jop/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/jop/agem/ according to the following timetable:

Manuscript DueFriday, 26 July 2013
First Round of ReviewsFriday, 18 October 2013
Publication DateFriday, 13 December 2013

Lead Guest Editor

Guest Editors

  • Gabriele Thumann, Department of Ophthalmology, University Hospital of Geneva, Geneva, Switzerland
  • Groll Jürgen, Department for Functional Materials in Medicine and Dentistry, University Hospital of Würzburg, Würzburg , Germany